Major Strides in HER2 Blockade for Metastatic Breast Cancer

被引：8
|
作者：
Sharma, Priyanka [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 07期
关键词：
TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; SURVIVAL;
D O I：
10.1056/NEJMe1916310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Breast cancer that is characterized by amplification or overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15 to 20% of all forms of the disease. The advent of HER2-targeted drugs, such as trastuzumab, pertuzumab, lapatinib, and the antibody-drug conjugate trastuzumab emtansine, has revolutionized the treatment of both early-stage and metastatic HER2-positive breast cancer.(1-4) The increasing availability of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, as reported in a study in which overall survival rose from a median of 38.7 months to 51.1 months from 2008 through 2012.(5) The standard first-line . . .
引用
收藏
页码：669 / 671
页数：3
相关论文
共 50 条
  • [31] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
    Advani, Pooja
    Cornell, Lauren
    Chumsri, Saranya
    Moreno-Aspitia, Alvaro
    BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
  • [32] Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna
    Arenas, Enrique J.
    Martinez-Sabadell, Alex
    Braso-Maristany, Fara
    Cervera, Raimundo
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Carbonell-Asins, Juan
    Simon, Soraya
    Poveda, Jesus
    Moragon, Santiago
    Zazo, Sandra
    Martinez, Debora
    Rovira, Ana
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Prat, Aleix
    Arribas, Joaquin
    Eroles, Pilar
    Miguel Cejalvo, Juan
    SCIENCE ADVANCES, 2022, 8 (20):
  • [33] TARGETING HER2-AXL HETERODIMERIZATION TO OVERCOME RESISTANCE TO HER2 BLOCKADE IN BREAST CANCER
    不详
    ESMO OPEN, 2022, 7 (04)
  • [34] A Comparative Analysis of the Value of Her2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of Her2 "LOW" Breast Cancers
    Bhardwaj, Swati
    Kandel, Avi
    Collins, Victoria
    Zeizafoun, Nebras
    Zeng, Jennifer
    Jaffer, Shabnam
    LABORATORY INVESTIGATION, 2023, 103 (03) : S103 - S103
  • [35] Cardiac toxicity in breast cancer patients treated with dual HER2 blockade
    Valachis, Antonis
    Nearchou, Andreas
    Polyzos, Nikolaos P.
    Lind, Pehr
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (09) : 2245 - 2252
  • [36] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [37] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Telli, Melinda L.
    Kimmick, Gretchen
    Winer, Eric
    Naughton, Michael
    Goetz, Matthew P.
    Russell, Christy
    Tripathy, Debu
    Cobleigh, Melody
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey
    Niravath, Polly Ann
    Thomas, Shana
    Anderson, Jill
    Bumb, Caroline
    Banks, Kimberly C.
    Lanman, Richard B.
    Bryce, Richard
    Lalani, Alshad S.
    Pfeifer, John
    Hayes, Daniel F.
    Pegram, Mark
    Blackwell, Kimberly
    Bedard, Philippe L.
    Al-Kateb, Hussam
    Ellis, Matthew J. C.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5687 - 5695
  • [38] Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
    Nozawa, Kazuki
    Takatsuka, Daiki
    Endo, Yuka
    Horisawa, Nanae
    Ozaki, Yuri
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 7
  • [39] Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
    Krizic, Marija
    Popovic, Marina
    Silovski, Tajana
    Grbin, Dorotea
    Plavetic, Natalija Dedic
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 413 - 423
  • [40] Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Le, Xiao-Feng
    Mao, Weiqun
    Lu, Chunhua
    Thornton, Angela
    Heymach, John V.
    Sood, Anil K.
    Bast, Robert C., Jr.
    CELL CYCLE, 2008, 7 (23) : 3747 - 3758
12345